From the Annual Meeting of the Consortium of MS Centers (CMSC), New Orleans

From Keith Edwards, MD   May 26, 2017

With the news of a MS patient in Germany who developed PML after 3 years of Tysabri and then one dose of ocrelizumab, the question of effectiveness and safety in ‘sequencing’ or switching from Tysabri (natalizumab) to another MS medication has become an even more important decision.  What is safe and yet effective to maintain stability in a MS patient who is at risk for PML after prolonged treatment with Tysabri has been a very important question for years.

Dr. Edwards presented a paper entitled: “Switching MS patients at risk for PML from natalizumab to teriflunomide:  Is it safe and effective?”

There is significant interest in this work among MS specialists to the extent that Dr Edwards’ research was referenced in the blog of 100 MS specialists this morning in a discussion about sequencing MS treatment.

Dr Edwards attended the CMSC meeting with 2 of the MS specialty infusion nurses from the MS Center in Latham, NY along with the nurse practitioner of the Center.  Besides presenting the above paper, Dr Edwards was co-author on 4 other papers involved with quality of life studies in MS.  The nurses and NP attended several conferences on the care of MS patients.

The MS Center of Northeastern New York, at 1205 Troy-Schenectady Road, Latham, is the only Comprehensive MS Care Center as recognized by the National MS Society in the greater Capital District.